US EditionUPDATE 1-Trump Says Price of Ozempic Will Be Lowered
The administration aims to cut Ozempic prices from $1,300 to $150 to boost affordability for diabetes and weight-loss patients, officials said.
- On Thursday, U.S. President Donald Trump said the price of Novo Nordisk's best-selling weight-loss drug would be lowered and negotiations would be swift at a White House event.
- Novo Nordisk's products include Ozempic for diabetes and Wegovy for weight-loss, and both contain the active ingredient semaglutide.
- President Donald Trump earlier said the price would fall to $150 from $1,300, and Ozempic has a list price of about $1,000 and is sold for $499 to cash-pay customers.
- A Novo Nordisk spokesperson said the company was focused on improving patient access and affordability and has engaged in discussions with the Administration regarding the Most Favoured Nation executive order.
- Dr. Mehmet Oz, Administrator of the Centers for Medicare and Medicaid Services , said the agency had not finished negotiating GLP-1 drug prices, while reporters noted Trump hesitated naming Ozempic or `the fat loss drug`.
15 Articles
15 Articles
Novo Nordisk fell about five percent on the stock exchange on Friday. The fall comes after US President Donald Trump once again reiterated his goal of lower prices for diet pills. In the fo...
Negotiations on a price change will proceed quickly, Trump says. Novo Nordisk confirms that there is dialogue.
The Epoch Times
The Political InsiderTrump Admin Negotiating to Lower Cost of Ozempic to $150
The Trump administration is in negotiations to obtain popular weight-loss drug Ozempic at a dramatically reduced price in the United States, according to President Donald Trump. The drug, made by Danish manufacturer Novo Nordisk, will be sold at most-favored nation pricing, meaning the lowest price available in developed countries. “In London, you’d buy a certain drug for $130 and even less than that … And in New York, you pay $1,300 for the sam…
US President Donald Trump said that the price of the best selling medicine for the weakened Novo Nordisk pharmaceutical company will be reduced and that negotiations on price changes will be fast,...
Coverage Details
Bias Distribution
- 42% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
